156 related articles for article (PubMed ID: 9783486)
21. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
[TBL] [Abstract][Full Text] [Related]
22. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left venticular hypertrophy.
Kohno M; Minami M; Kano H; Yasunari K; Maeda K; Hanehira T; Yoshikawa J
Metabolism; 2000 Oct; 49(10):1356-60. PubMed ID: 11079829
[TBL] [Abstract][Full Text] [Related]
23. Selection of antihypertensive therapy: cardiac and extracardiac considerations.
Messerli FH; Soria F
Cardiology; 1992; 81(4-5):316-24. PubMed ID: 1301259
[TBL] [Abstract][Full Text] [Related]
24. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Ikeda Y; Nakamura T; Takano H; Kimura H; Obata JE; Takeda S; Hata A; Shido K; Mochizuki S; Yoshida Y
J Lab Clin Med; 2000 Apr; 135(4):353-9. PubMed ID: 10779052
[TBL] [Abstract][Full Text] [Related]
26. Silent myocardial ischaemia in treated hypertensives with and without left ventricular hypertrophy.
Stojanovic MM; O'Brien E; Lyons S; Stanton AV
Blood Press Monit; 2003 Feb; 8(1):45-51. PubMed ID: 12604937
[TBL] [Abstract][Full Text] [Related]
27. Association of left atrial enlargement with left ventricular hypertrophy and diastolic dysfunction: a tissue Doppler study in echocardiographic practice.
Cuspidi C; Negri F; Sala C; Valerio C; Mancia G
Blood Press; 2012 Feb; 21(1):24-30. PubMed ID: 21992028
[TBL] [Abstract][Full Text] [Related]
28. Myocardial abnormalities in hypertensive patients with normal and abnormal left ventricular filling: a study of ultrasound tissue characterization and strain.
Yuda S; Short L; Leano R; Marwick TH
Clin Sci (Lond); 2002 Sep; 103(3):283-93. PubMed ID: 12193154
[TBL] [Abstract][Full Text] [Related]
29. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects.
Verdecchia P; Angeli F; Gattobigio R; Sardone M; Pede S; Reboldi GP
Am J Hypertens; 2006 May; 19(5):493-9. PubMed ID: 16647622
[TBL] [Abstract][Full Text] [Related]
30. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.
Pierdomenico SD; Lapenna D; Cuccurullo F
Am J Hypertens; 2008 Apr; 21(4):464-70. PubMed ID: 18369364
[TBL] [Abstract][Full Text] [Related]
31. Left ventricular hypertrophy and heart failure in women.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
[TBL] [Abstract][Full Text] [Related]
32. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
33. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality.
Kaplinsky E
Cardiovasc Drugs Ther; 1994 Aug; 8 Suppl 3():549-56. PubMed ID: 7841088
[TBL] [Abstract][Full Text] [Related]
34. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
[TBL] [Abstract][Full Text] [Related]
35. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.
Mayet J; Ariff B; Wasan B; Chapman N; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA
Hypertension; 2000 Nov; 36(5):755-9. PubMed ID: 11082139
[TBL] [Abstract][Full Text] [Related]
36. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
37. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis.
Verdecchia P; Angeli F; Borgioni C; Gattobigio R; de Simone G; Devereux RB; Porcellati C
Am J Hypertens; 2003 Nov; 16(11 Pt 1):895-9. PubMed ID: 14573325
[TBL] [Abstract][Full Text] [Related]
38. Age related prevalence of severe left ventricular hypertrophy in essential hypertension: echocardiographic findings from the ETODH study.
Cuspidi C; Meani S; Sala C; Valerio C; Negri F; Mancia G
Blood Press; 2012 Jun; 21(3):139-45. PubMed ID: 22416806
[TBL] [Abstract][Full Text] [Related]
39. Hypertension and sudden cardiac death.
Messerli FH
Am J Hypertens; 1999 Dec; 12(12 Pt 3):181S-188S. PubMed ID: 10619570
[TBL] [Abstract][Full Text] [Related]
40. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis.
Brilla CG; Matsubara L; Weber KT
Hypertension; 1996 Aug; 28(2):269-75. PubMed ID: 8707393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
